Shares of oncology-focused biopharmaceutical company Arcus Biosciences, Inc. (RCUS) are trading 15 percent higher on Thursday. The company on Wednesday reported positive clinical activity from its three-arm randomized Phase 2 ARC-7 study.
The company said that the first interim analysis of the three-arm...